Jacob P Kelly1, Allison Dunning2, Phillip J Schulte3, Mona Fiuzat4, Eric S Leifer5, Jerome L Fleg5, Lawton S Cooper5, Steven J Keteyian6, Dalane W Kitzman7, Ileana L Pina8, William E Kraus9, David J Whellan10, Christopher M O'Connor4, Robert J Mentz4. 1. Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina. Electronic address: Jacob.kelly@duke.edu. 2. Duke Clinical Research Institute, Durham, North Carolina. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 4. Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina. 5. Division of Cardiovascular Science, National Heart, Lung, and Blood Institute, Bethesda, Maryland. 6. Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan. 7. Section of Cardiology, Department of Internal Medicine, Wake Forest University, Winston-Salem, North Carolina. 8. Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine, New York, New York. 9. Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Molecular Physiology Institute, Durham, North Carolina. 10. Division of Cardiology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract
OBJECTIVES: The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. BACKGROUND: Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failure (HF). METHODS: HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction ≤35% who were randomized to usual care with or without ET. We evaluated whether there was a treatment interaction between statins and ET response for the change in quality of life and aerobic capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, adjusting for baseline covariates. RESULTS: Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence of a treatment interaction between statin use and ET on changes in quality of life or exercise capacity, nor was there evidence of differential association between statin type and ET response for these endpoints (all p values >0.05). CONCLUSIONS: In a large chronic HF cohort, there was no evidence of a treatment interaction between statin use and short-term change in aerobic capacity and quality of life with ET. These findings contrast with recent reports of an attenuation in ET response with statins in a different population, highlighting the need for future prospective studies. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).
RCT Entities:
OBJECTIVES: The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. BACKGROUND: Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failure (HF). METHODS: HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) was a randomized trial of 2,331 patients with chronic HF with ejection fraction ≤35% who were randomized to usual care with or without ET. We evaluated whether there was a treatment interaction between statins and ET response for the change in quality of life and aerobic capacity (peak oxygen consumption and 6-min walk distance) from baseline to 3 months. We also assessed for a treatment interaction among atorvastatin, simvastatin, and pravastatin and change in these endpoints with ET. Multiple linear regression analyses were performed for each endpoint, adjusting for baseline covariates. RESULTS: Of 2,331 patients in the HF-ACTION trial, 1,353 (58%) were prescribed statins at baseline. Patients treated with statins were more likely to be older men with ischemic HF etiology but had similar use of renin angiotensin system blockers and beta-blockers. There was no evidence of a treatment interaction between statin use and ET on changes in quality of life or exercise capacity, nor was there evidence of differential association between statin type and ET response for these endpoints (all p values >0.05). CONCLUSIONS: In a large chronic HF cohort, there was no evidence of a treatment interaction between statin use and short-term change in aerobic capacity and quality of life with ET. These findings contrast with recent reports of an attenuation in ET response with statins in a different population, highlighting the need for future prospective studies. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).
Authors: Beth A Parker; Amanda L Augeri; Jeffrey A Capizzi; Kevin D Ballard; Christopher Troyanos; Aaron L Baggish; Pierre A D'Hemecourt; Paul D Thompson Journal: Am J Cardiol Date: 2011-10-28 Impact factor: 2.778
Authors: Robert J Mentz; Vera Bittner; Phillip J Schulte; Jerome L Fleg; Ileana L Piña; Steven J Keteyian; Gordon Moe; Anil Nigam; Ann M Swank; Anekwe E Onwuanyi; Meredith Fitz-Gerald; Andrew Kao; Stephen J Ellis; William E Kraus; David J Whellan; Christopher M O'Connor Journal: Am Heart J Date: 2013-07-12 Impact factor: 4.749
Authors: David J Whellan; Christopher M O'Connor; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston-Miller; Jerome L Fleg; Kevin A Schulman; Ileana L Piña Journal: Am Heart J Date: 2007-02 Impact factor: 4.749
Authors: Catherine R Mikus; Leryn J Boyle; Sarah J Borengasser; Douglas J Oberlin; Scott P Naples; Justin Fletcher; Grace M Meers; Meghan Ruebel; M Harold Laughlin; Kevin C Dellsperger; Paul J Fadel; John P Thyfault Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094
Authors: Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Robert J Mentz; Phillip J Schulte; Jerome L Fleg; Mona Fiuzat; William E Kraus; Ileana L Piña; Steven J Keteyian; Dalane W Kitzman; David J Whellan; Stephen J Ellis; Christopher M O'Connor Journal: Am Heart J Date: 2012-11-28 Impact factor: 4.749
Authors: Linda Long; Ify R Mordi; Charlene Bridges; Viral A Sagar; Edward J Davies; Andrew Js Coats; Hasnain Dalal; Karen Rees; Sally J Singh; Rod S Taylor Journal: Cochrane Database Syst Rev Date: 2019-01-29